Business
Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development
SAN DIEGO--(BUSINESS WIRE)-- Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel
About this update from Janux Therapeutics, Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nJanux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Dr. Zachariah (“Zach”) McIver as Vice President, Clinical Development. An accomplished physician-scientist with more than 15 years of experience in clinical research, Dr. McIver joins Janux after serving as Amgen’s Executive Medical Director, where he led cross-functional teams in the design, implementation, and execution of clinical and correlative study strategies.\n\n\n“Zach has extensive clinical research experience including leading the clinical development to maximize the value of bispecific T-cell engager assets across multiple hematologic and solid tumor malignancies,” said David Campbell, Ph.D., President and CEO of Janux Therapeutics. “At Janux, Zach will play a key role in clinical development oversight as we advance our novel immunotherapy programs through clinical trials.”\n\n\n“We’re excited to have Zach join the team as his experience with advanced T-cell engager programs will be especially important as we continue to advance our drug candidates in clinical trials,” said Wayne Godfrey, M.D., Chief Medical Officer at Janux.\n\n\n“With TRACTr and TRACIr, Janux has built two very powerful platforms designed to overcome the toxicity and efficacy limitations of earlier generations of bispecific immunotherapies,” said Dr. McIver. “I look forward to working with the team at Janux to advance the Company’s deep portfolio of next-generation bispecific immunotherapies to improve cancer treatment and help more patients.”\n\n\nA board-certified hematologist and physician-scientist, Dr. McIver began his career specializing in hematological malignancies and immunotherapy working as a principal investigator at the Hematology Branch of the National Heart, Lung, and Blood Institute (NHLBI) at the National Institute of Health (NIH). He played a key role in developing novel small molecules targeting alloreactive T-cells to prevent graft-versus-host-disease (GVHD) and established a stem cell transplant program for racial minority populations at the Wake Forest University School of Medicin...